Invention Grant
- Patent Title: Cell-based assay for determining activity in the retinoblastoma pathway
-
Application No.: US17502217Application Date: 2021-10-15
-
Publication No.: US11702666B2Publication Date: 2023-07-18
- Inventor: Tatyana Naryshkina
- Applicant: Medical Diagnostic Laboratories, LLC
- Applicant Address: US NJ Hamilton
- Assignee: Medical Diagnostic Laboratories, LLC
- Current Assignee: Medical Diagnostic Laboratories, LLC
- Current Assignee Address: US NJ Hamilton
- Agent Arnold Braun; Jessica Dowling
- Main IPC: C12N15/79
- IPC: C12N15/79 ; C12N9/02 ; G01N33/50 ; C12Q1/48 ; C12N9/12

Abstract:
Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
Public/Granted literature
- US20220073935A1 Novel Cell-Based Assay for Determining Activity in the Retinoblastoma Pathway Public/Granted day:2022-03-10
Information query
IPC分类: